Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (281-290 of 441) with videos related to

Pageof 45
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapySiraj M Ali, R Katherine Alpaugh, Sean R Downing, et al.
American Journal of Clinical Oncology|May 8, 2013
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed TherapyChiaojung Jillian Tsai, Jing Li, Ana M Gonzalez-Angulo, et al.
Breast Cancer Research and Treatment|December 15, 2012
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancerMassimo Cristofanilli, Stephen R D Johnston, Alexey Manikhas, et al.
International Journal of Molecular Sciences|February 21, 2020
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast CancerJennifer S Winn, Zachary Hasse, Michael Slifker, et al.
Oncotarget|September 3, 2016
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNAYoung Kwang Chae, Andrew A Davis, Benedito A Carneiro, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
AJNR. American Journal of Neuroradiology|March 26, 2026
Dynamic Brain [F18]-Fluoroestradiol (FES) PET Protocol Optimization for Improved Detection of Breast Cancer Brain MetastasesEzzat Elmoujarkach, Arman Sharbatdaran, Letizia Pontolillo, et al.
Clinical Breast Cancer|January 9, 2023
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain MetastasesAmi N Shah, Cesar A Santa-Maria, Dhruvika Mukhija, et al.
Cancers|June 24, 2022
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance MechanismMaysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Pageof 45

Showing results (281-290 of 441) with videos related to

Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapySiraj M Ali, R Katherine Alpaugh, Sean R Downing, et al.
American Journal of Clinical Oncology|May 8, 2013
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed TherapyChiaojung Jillian Tsai, Jing Li, Ana M Gonzalez-Angulo, et al.
Breast Cancer Research and Treatment|December 15, 2012
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancerMassimo Cristofanilli, Stephen R D Johnston, Alexey Manikhas, et al.
International Journal of Molecular Sciences|February 21, 2020
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast CancerJennifer S Winn, Zachary Hasse, Michael Slifker, et al.
Oncotarget|September 3, 2016
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNAYoung Kwang Chae, Andrew A Davis, Benedito A Carneiro, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
AJNR. American Journal of Neuroradiology|March 26, 2026
Dynamic Brain [F18]-Fluoroestradiol (FES) PET Protocol Optimization for Improved Detection of Breast Cancer Brain MetastasesEzzat Elmoujarkach, Arman Sharbatdaran, Letizia Pontolillo, et al.
Clinical Breast Cancer|January 9, 2023
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain MetastasesAmi N Shah, Cesar A Santa-Maria, Dhruvika Mukhija, et al.
Cancers|June 24, 2022
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance MechanismMaysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Pageof 45